Statin Labeling Changes Include Class Warning About Glucose Effects
This article was originally published in The Pink Sheet Daily
Executive Summary
All statin labels now warn that “increases in HbA1C and fasting serum glucose levels have been reported” with the cholesterol-lowering drugs. Labels also reflect a relaxation of hepatic monitoring requirements, which could remove one hurdle to Pfizer’s pursuit of an OTC switch for Lipitor.